ArticleSurgical endoscopy2026
SSRI monotherapy impacts weight loss outcomes following bariatric surgery.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for anxiety and depression among patients undergoing metabolic and bariatric surgery (MBS). SSRIs are associated with weight gain in the general population, and therefore may potentially hinder weight loss post-bariatric surgery. This study evaluated the effect of continued SSRI monotherapy on weight loss outcomes following sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB).
methodsA retrospective cohort study of adults who underwent SG or RYGB between July 2020 and June 2023 was conducted. Patients with depression or anxiety receiving SSRI monotherapy before surgery and continuing treatment for at least 12 months postoperatively were compared with patients without depression or anxiety by surgical procedure. Propensity-score matching was performed in a 1:1 ratio using demographic and clinical variables. Primary outcomes were total weight loss percentage (TWL%) and excess weight loss percentage (EWL%) at 3, 6, and 12 months.
resultsAmong 799 patients, 731 were included in the no anxiety/depression (No A/D) group and 68 in the anxiety/depression with SSRI monotherapy (A/D SSRI) group. Unadjusted analyses demonstrated no significant differences in TWL% or EWL% between groups in either procedural cohort. Following propensity-score matching, patients undergoing SG in the A/D SSRI group achieved significantly lower EWL% at 3 months (32.5 vs. 42.8%, p = 0.035) and 12 months (47.3 vs. 63.5%, p < 0.001), as well as lower TWL% at 3 months (15.1 vs. 20.0%, p = 0.015) and 12 months (22.4 vs. 28.5%, p = 0.034). No significant differences in TWL% or EWL% were observed at any time point among patients undergoing RYGB (p > 0.274).
conclusionsContinued SSRI monotherapy may be associated with inferior short- and intermediate-term weight loss following sleeve gastrectomy, but does not appear to adversely affect weight loss after Roux-en-Y gastric bypass. These findings may inform preoperative counseling, procedure selection, and postoperative management of bariatric patients receiving SSRI therapy.
Indexed as
Identifiers
42728436What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.